Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.19 and traded as high as $9.45. DBV Technologies shares last traded at $9.01, with a volume of 47,375 shares trading hands.
Wall Street Analysts Forecast Growth
DBVT has been the topic of several analyst reports. HC Wainwright boosted their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday. StockNews.com started coverage on shares of DBV Technologies in a report on Thursday, May 1st. They set a "hold" rating on the stock. Finally, JMP Securities increased their price objective on DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a report on Thursday, May 1st.
View Our Latest Stock Analysis on DBV Technologies
DBV Technologies Stock Up 1.5 %
The firm's 50-day simple moving average is $6.58 and its 200-day simple moving average is $4.75. The firm has a market capitalization of $261.03 million, a P/E ratio of -2.12 and a beta of -0.66.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) EPS for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The business had revenue of $0.51 million for the quarter. As a group, analysts expect that DBV Technologies S.A. will post -7.05 EPS for the current fiscal year.
Hedge Funds Weigh In On DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Further Reading
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
